Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

First de novo deuterated drug poised for approval

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Nature Reviews Drug Discovery 21, 623-625 (2022)


Updates & Corrections

  • Correction 18 August 2022: The text has been updated to reflect that phase III trials of deucravacitinib for systemic lupus erythematosus are planned rather than ongoing, and to clarify the role of Celgene in the development of NDI-034858.

Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links